Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products
- PMID: 16288898
- DOI: 10.1016/j.biocel.2005.09.016
Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products
Abstract
Objective: The mechanisms whereby advanced glycation end products (AGE) contribute to atherogenesis in diabetes mellitus are not fully understood. In this study we analyzed in vitro the influence of advanced glycated albumin (AGE-albumin) as well as the role of the AGE inhibitors--aminoguanidine (AMG) and metformin (MF)--on the cell cholesterol efflux.
Methods: HDL3 and albumin-mediated cholesterol efflux was measured in mouse peritoneal macrophages and in SR-BI transfected cells that had been treated along time with dicarbonyl sugars or AGE-albumin, both in the presence or in the absence of AMG and MF. 125I-HDL3 cell binding and 125I-AGE-albumin cell degradation were measured. Carboxymethyllysine (CML) formation and SR-BI expressions were determined by immunoblot.
Results: AGE-albumin efficiently trapped cell cholesterol but impaired the HDL-mediated cell cholesterol efflux by decreasing HDL binding to the cell surface and inducing intracellular glycoxidation, without interfering with the SR-BI expression. Cell treatment with dicarbonyl sugars also disrupted the HDL-mediated cell cholesterol efflux, but this was prevented by AMG and MF that reduced CML formation.
Conclusions: By adversely impairing the HDL-mediated cell cholesterol removal rate, AGE-albumin and cell glycoxidation could facilitate the development of premature atherosclerosis in diabetes mellitus (DM) and in other diseases associated with carbonyl and oxidative stress like in chronic uremia. Thus, drugs that prevent AGE formation may be useful to correct disturbances in cell cholesterol transport.
Similar articles
-
Metformin restores impaired HDL-mediated cholesterol efflux due to glycation.Atherosclerosis. 2009 Oct;206(2):434-8. doi: 10.1016/j.atherosclerosis.2009.03.003. Epub 2009 Mar 19. Atherosclerosis. 2009. PMID: 19376519
-
Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal.Clin Chim Acta. 2005 Aug;358(1-2):139-45. doi: 10.1016/j.cccn.2005.02.012. Clin Chim Acta. 2005. PMID: 15946656
-
Oxidative stress mediates protein kinase C activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet.Am J Nephrol. 2009;29(3):171-80. doi: 10.1159/000154470. Epub 2008 Sep 8. Am J Nephrol. 2009. PMID: 18781061
-
Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.Drug Discov Today. 2006 Jul;11(13-14):646-54. doi: 10.1016/j.drudis.2006.05.016. Drug Discov Today. 2006. PMID: 16793534 Review.
-
The AGE/RAGE axis in diabetes-accelerated atherosclerosis.Clin Exp Pharmacol Physiol. 2008 Mar;35(3):329-34. doi: 10.1111/j.1440-1681.2007.04875.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18290873 Review.
Cited by
-
Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages.PLoS One. 2013 May 31;8(5):e65430. doi: 10.1371/journal.pone.0065430. Print 2013. PLoS One. 2013. PMID: 23741493 Free PMC article.
-
RAGE Mediates Cholesterol Efflux Impairment in Macrophages Caused by Human Advanced Glycated Albumin.Int J Mol Sci. 2020 Oct 1;21(19):7265. doi: 10.3390/ijms21197265. Int J Mol Sci. 2020. PMID: 33019603 Free PMC article.
-
Proteomics of high-density lipoprotein subfractions and subclinical atherosclerosis in type 1 diabetes mellitus: a case-control study.Diabetol Metab Syndr. 2023 Mar 11;15(1):42. doi: 10.1186/s13098-023-01007-y. Diabetol Metab Syndr. 2023. PMID: 36899434 Free PMC article.
-
Advanced Glycated apoA-IV Loses Its Ability to Prevent the LPS-Induced Reduction in Cholesterol Efflux-Related Gene Expression in Macrophages.Mediators Inflamm. 2020 Jan 14;2020:6515401. doi: 10.1155/2020/6515401. eCollection 2020. Mediators Inflamm. 2020. PMID: 32410861 Free PMC article.
-
Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.Diabetologia. 2008 Jun;51(6):1008-17. doi: 10.1007/s00125-008-0986-z. Epub 2008 Apr 24. Diabetologia. 2008. PMID: 18437350
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials